Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications

References

• LeskeMCHeijlAHusseinMBengtssonBHymanLKomaroffEEarly Manifest Glaucoma Trial GroupFactors for glaucoma progression and the effect of treatment: the early manifest glaucoma trialArch Ophthalmol20031211485612523884
   PubMedGoogle Scholar
• European Glaucoma SocietyTerminology and guidelines for glaucoma4th edition Available at: http://bjo.bmj.com/content/bjophthalmol/101/4/1.full.pdfAccessed September 13, 2017
   Google Scholar
• AptelFCucheratMDenisPEfficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trialsJ Glaucoma200817866767319092464
   PubMed Web of Science ®Google Scholar
• van der ValkRWebersCALumleyTHendrikseFPrinsMHSchoutenJSA network meta-analysis combined direct and indirect comparisons between glaucoma drugs to rank effectiveness in lowering intraocular pressureJ Clin Epidemiol200962121279128319716679
   PubMed Web of Science ®Google Scholar
• LeeAJMcCluskeyPClinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertensionClin Ophthalmol2010474176420689791
   PubMedGoogle Scholar
• LinLZhaoYJChewPTComparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertensionAnn Pharmacother201448121585159325184309
   PubMed Web of Science ®Google Scholar
• American Academy of OphthalmologyPrimary open-angle glaucoma Available at: http://www.aaojournal.org/article/S0161-6420(15)01276-2/pdfAccessed May 25, 2017
   Google Scholar
• KassMAHeuerDKHigginbothamEJThe Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucomaArch Ophthalmol20021206701713 discussion 829–83012049574
   PubMed Web of Science ®Google Scholar
• HólloGTopouzisFFechtnerRDFixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practiceExpert Opin Pharmacother201415121737174724998246
   PubMed Web of Science ®Google Scholar
• OlthoffCMSchoutenJSvan de BorneBWWebersCANoncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension: an evidence-based reviewOphthalmology2005112695396115885795
   PubMed Web of Science ®Google Scholar
• RobinALCovertDDoes adjunctive glaucoma therapy affect adherence to the initial primary therapy?Ophthalmology2005112586386815878067
   PubMed Web of Science ®Google Scholar
• Alcon Laboratories IncTimolol GFS (timolol maleate ophthalmic gel forming solution) 0.25% and 0.5%, Sterile topical ophthalmic drops. [Highlights of prescribing information (6/2007)] Available at: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4399b1-58%20(Timolol%20GFS%20(timolol)%20Labeling).pdfAccessed May 25, 2017
   Google Scholar
• Pfizer IncXALATAN^® (latanoprost ophthalmic solution) 0.005%. [Highlights of prescribing information (4/2017)] Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=613Accessed May 25, 2017
   Google Scholar
• Allergan plcALPHAGAN^® P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15%. [Highlights of prescribing information (9/2013)] Available at: http://www.allergan.com/assets/pdf/alphaganp_pi.pdfAccessed May 25, 2017
   Google Scholar
• Allergan plcLUMIGAN^® (bimatoprost ophthalmic solution) 0.01% for topical ophthalmic use. [Highlights of prescribing information (10/2016)] Available at: http://www.allergan.com/assets/pdf/lumigan_pi.pdfAccessed May 25, 2017
   Google Scholar
• SherwoodMBrandtJSix-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressureSurv Ophthalmol200145Suppl 4S361S36811434939
   PubMed Web of Science ®Google Scholar
• BrandtJDVanDenburghAMChenKWhitcupSMComparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trialOphthalmology2001108610231031 discussion 103211382623
   PubMed Web of Science ®Google Scholar
• HigginbothamEJSchumanJSGoldbergIOne-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertensionArch Ophthalmol2002120101286129312365906
   PubMed Web of Science ®Google Scholar
• WhitcupSMCantorLBVanDenburghAMChenKA randomised, double masked, multicentre clinical trial comparing bimatoprost and timolol for the treatment of glaucoma and ocular hypertensionBr J Ophthalmol2003871576212488264
   PubMed Web of Science ®Google Scholar
• CohenJSGrossRLCheethamJKVanDenburghAMBernsteinPWhitcupSMTwo-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertensionSurv Ophthalmol200449Suppl 1S45S5215016561
   PubMed Web of Science ®Google Scholar
• KatzLJCohenJSBatoosinghALFelixCShuVSchiffmanRMTwelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertensionAm J Ophthalmol20101494661671.e120346780
   PubMed Web of Science ®Google Scholar
• NixonDRSimonyiSBhogalMAn observational study of bimatoprost 0.01% in treatment-naïve patients with primary open angle glaucoma or ocular hypertension: the CLEAR trialClin Ophthalmol201262097210323269858
   PubMedGoogle Scholar
• PfennigsdorfSRamezOvon KistowskiGMulticenter, prospective, open-label, observational study of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertensionClin Ophthalmol2012673974622654501
   PubMedGoogle Scholar
• FigusMNardiMPiaggiPBimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patientsEye201428442242924434659
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyAssessment report for Lumigan (January 2010) Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000391/WC500074096.pdfAccessed May 25, 2017
   Google Scholar
• TsonisPAAnimal models in eye researchNew YorkElsevier Academic Press2011
   Google Scholar
• FarageMAMaibachHIAndersenKEHistorical perspective on the use of visual grading scales in evaluating skin irritation and sensitizationContact Dermatitis2011652657521668861
   PubMed Web of Science ®Google Scholar
• MatsuoTCynaderMSLocalisation of prostaglandin F2 alpha and E2 binding sites in the human eyeBr J Ophthalmol19927642102131327095
   PubMed Web of Science ®Google Scholar
• MauriceDThe effect of the low blink rate in rabbits on topical drug penetrationJ Ocul Pharmacol Ther19951132973048590262
   PubMed Web of Science ®Google Scholar
• CrichtonACNixonDRSimonyiSAn observational study of bimatoprost 0.01% in patients on prior intraocular pressure-lowering therapy: the Canadian Lumigan((R)) RC Early Analysis Review (CLEAR) trialClin Ophthalmol201481031103824920879
   PubMedGoogle Scholar
• MyersJSVoldSZamanFWilliamsJMHollanderDABimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trialsClin Ophthalmol2014864365224707169
   PubMedGoogle Scholar
• LaibovitzRAVanDenburghAMFelixCComparison of the ocular hypotensive lipid AGN 192024 with timolol: dosing, efficacy, and safety evaluation of a novel compound for glaucoma managementArch Ophthalmol20011197994100011448321
   PubMedGoogle Scholar
• Allergan plcA Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension Available at: https://clinicaltrials.gov/ct2/show/NCT01863953?term=NCT01863953&rank=1. ClinicalTrials.gov identifier: NCT01863953Accessed September 5, 2017
   Google Scholar
• ParraJCHartlebenCMBatoosinghABernsteinPGoodkinMBimatoprost/Brimonidine/Timolol vs Brimonidine/Timolol Fixed Combinations in Glaucoma: A Randomized, Double-Masked Studypresented at the XXXI Congreso Panamericano de OftalmologíaAug 4–8, 2015Bogotá, Colombia
   Google Scholar
• BelfortRJrPaulaJSJordaoMKimTChenMYGoodkinMTriple Fixed Combination Bimatoprost/Brimonidine/Timolol Versus Dual Fixed Combination Brimonidine/Timolol Ophthalmic Solutions in Glaucoma: A Multicenter, Randomized, Double-Masked Studypresented at the 60th Congresso Brasileiro de OftalmologiaSept 3–6, 2016Goiânia, Brazil Available at: https://cbo2016.com.br/cbo2016/programacao/resumo?trabalho=35Accessed September 5, 2017
   Google Scholar